New opportunities for local therapy of pustular skin diseases

Aim. To study the effectiveness of a universal antiseptic Betadine (international nonproprietary name - povidone-iodine) in the treatment of pustular skin diseases. Methods. The study had the form of an open, non-comparative one, which involved 25 patients aged from 2.5 to 40 years (mean age 16.1±1.2 years) with disease duration from 1 to 7 days (mean 4.2±0.8) with various forms of pyoderma: 21 patients with streptococcal impetigo and 4 patients with folliculitis. Assessment of safety of the study was carried out on the basis of clinical and laboratory data, patient tolerability of the substance, the expert-opinion of the physician-researcher. Changes in the quality of life as a result of treatment of patients with pyoderma using Betadine solution was evaluated by a questionnaire SKINDEKS-29. Results. All patients willing used the proposed betadine solution. No reasons for discontinuation of treatment during the study (including side effects, allergic reactions or exacerbation of the cutaneous process) were identified. Deterioration of the quality of life on the «Emotions» scale of SKINDEKS-29 questionnaire at the beginning of treatment was 49.8±1.3 points («sometimes»), during the second visit - 26.8±0.9 points («rarely»), by the end of treatment (third visit) - 10.2±0.3 points («no»); on a scale of «Function» at the beginning of treatment - 77.8±1.8 («often»), during the second visit - 53.2±1.6 («sometimes»), by the end of treatment - 16.2±0.8 points («no»); on a scale of «Symptoms» at the beginning of treatment - 51.2±1.3 («sometimes»), during the second visit - 27.6±2.8 («rarely»), by the end of treatment - 12.3±0.3 points («no»). Conclusion. Betadine is characterized by high clinical efficacy in pustular skin diseases, good tolerance, absence of adverse reactions, a positive impact on the quality of life and can be recommended as a therapeutic and prophylactic agent.

pustular skin diseases, universal antiseptic Betadine